HC Wainwright & Co. Initiates Coverage On Mural Oncology with Buy Rating, Announces Price Target of $18

Benzinga · 10/17 10:58
HC Wainwright & Co. analyst Andres Maldonado initiates coverage on Mural Oncology (NASDAQ:MURA) with a Buy rating and announces Price Target of $18.